Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLUMBIA-2
NCT04145193Phase 2Withdrawn
- Sponsor
- MedImmune
- Start
- Oct 2020
- Primary completion
- Mar 2024
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
01
Overview
A Phase 2 trial of durvalumab, oleclumab, monalizumab in microsatellite stable colorectal cancer, sponsored by MedImmune. Planned start Oct 2020; status: withdrawn.
02
Drugs
durvalumaboleclumabmonalizumab
03
Conditions
microsatellite stable colorectal cancer
Beyond the preview
Go deeper on NCT04145193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145193.